Related Experiment Video
Updated: Jun 16, 2025
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer's disease
Noemi Sola-Sevilla1, Maider Garmendia-Berges2, Mikel Aleixo2
1Department of Pharmaceutical Sciences, Division of Pharmacology, University of Navarra, 31008 Pamplona, Spain; IdISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain; Department of Neurology, Research Center for Immunotherapy (FZI) and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz 55131 Mainz, Germany.
Abstract:
Sirtuin 2 (SIRT2), a NAD+-dependent deacetylase, has been implicated in aging and neurodegenerative diseases such as Alzheimer's disease (AD). While global SIRT2 inhibition has shown promise in reducing amyloid-beta pathology and cognitive deficits in different mouse models of AD, peripheral SIRT2 inhibition has been associated with adverse effects, such as increased inflammation. This suggests that targeted inhibition of specific cellular populations within the brain may represent a more precise and effective approach for the treatment of AD. To explore this hypothesis, we generated a conditional microglial SIRT2 knockout mouse model in the context of AD. Our results reveal that microglial SIRT2 reduction does not confer protective effects in the APP/PS1 model; rather, it aggravates cognitive decline, accelerates amyloid plaque deposition, and increases levels of pro-inflammatory cytokines at early stages of AD pathology. Transcriptomic analysis further indicates that SIRT2-deficient microglia exhibit altered expression of genes associated with aging and synaptic dysfunction. This phenotype was accompanied by increased phagocytosis of PSD95 and impaired long-term potentiation. These findings suggest that while SIRT2 inhibition in some contexts may be beneficial, targeted inhibition within microglia could accelerate AD progression, underscoring the need for cell-specific approaches when considering SIRT2 as a therapeutic target.
Insights
Targeting Sirtuin 2 (SIRT2) in microglia worsens Alzheimer's disease (AD) progression, accelerating cognitive decline and amyloid plaque deposition. Cell-specific approaches are crucial for therapeutic strategies targeting SIRT2 in AD.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Sirtuin 2 (SIRT2) is a NAD+-dependent deacetylase linked to aging and neurodegenerative diseases like Alzheimer's disease (AD).
- Global SIRT2 inhibition shows therapeutic potential in AD mouse models, but peripheral inhibition causes adverse effects like inflammation.
- Targeting specific brain cell populations may offer a more precise therapeutic strategy for AD.
Purpose of the Study:
- To investigate the effects of microglial-specific SIRT2 knockout on Alzheimer's disease (AD) pathology.
- To determine if targeting SIRT2 within microglia is a viable therapeutic strategy for AD.
Main Methods:
- Generation of a conditional microglial SIRT2 knockout mouse model in the context of AD (APP/PS1 model).
- Assessment of cognitive function, amyloid plaque deposition, and pro-inflammatory cytokine levels.
- Transcriptomic analysis of SIRT2-deficient microglia.
- Evaluation of microglial phagocytosis and long-term potentiation (LTP).
Main Results:
- Microglial SIRT2 reduction aggravated cognitive decline and accelerated amyloid plaque deposition in the APP/PS1 mouse model.
- Increased levels of pro-inflammatory cytokines were observed at early stages of AD pathology.
- SIRT2-deficient microglia showed altered gene expression related to aging and synaptic dysfunction, increased PSD95 phagocytosis, and impaired LTP.
Conclusions:
- Targeted inhibition of SIRT2 within microglia does not confer protective effects and may accelerate AD progression.
- Cell-specific approaches are essential when considering SIRT2 as a therapeutic target for Alzheimer's disease.
- Microglial SIRT2 plays a critical role in modulating AD pathology and synaptic function.
